Quantcast

Industry news that matters to you.  Learn more

Archives for August 2010

NIH to Fund Research on Alcohol-related Biomarkers

The National Institute on Alcohol Abuse and Alcoholism aims to fund small businesses and support the technology transfer of new biomarkers that can be used to detect alcohol-related organ damage and fetal exposure to alcohol, according to a new NIAAA grant notice.

Aterovax and Biomnis Join to Offer sPLA2 Biomarker to Trial Sector

Aterovax has teamed up with Biomnis to target the clinical trial industry with a new atherosclerosis biomarker, sPLA2, designed to give researchers better insight into a candidate heart drug’s therapeutic potential.

Unlike related biomarkers markers, which generally measure only one isoform of the human secreted phospholipases A2 (sPLA2) enzyme, Aterovax claim their new activity test is capable of measuring the “full family”.

Chronix Biomedical Adds State-of-the-art Mass Seqeuncing Capabilities to Accelerate Development of it’s DNA Biomakers for Early Detection of Cancer

Chronix Biomedical today reported that it has significantly expanded and accelerated its biomarker development capabilities with the installation of Germany’s first state-of-the-art high-throughput DNA mass sequencer at the University of Göttingen, Chronix’s long-time collaborator. Chronix is developing disease-specific biomarkers based on DNA fragments that are released into the bloodstream by damaged and dying (apoptotic) cells. Chronix‘s serum DNA biomarkers are applicable to a wide range of cancers and other chronic diseases.

Creatine Kinase-MB Wins at Predicting Cardiac Outcomes

Myocardium specific creatine kinase levels appear to provide a better prognosis of long-term outcomes for elective heart surgery patients than do measures of troponin, according to a prospective study.

The Cancer Biomarker Conundrum: Too Many False Discoveries

The boom in cancer biomarker investments over the past 25 years has not translated into major clinical success. The reasons for biomarker failures include problems with study design and interpretation, as well as statistical deficiencies, according to an article published online August 12 in The Journal of the National Cancer Institute.